Product: SOCS1 Antibody
Catalog: AF5378
Description: Rabbit polyclonal antibody to SOCS1
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Rabbit, Dog
Mol.Wt.: 25~35 kD; 24kD(Calculated).
Uniprot: O15524
RRID: AB_2837863

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(90%), Rabbit(100%), Dog(100%)
Clonality:
Polyclonal
Specificity:
SOCS1 Antibody detects endogenous levels of total SOCS1.
RRID:
AB_2837863
Cite Format: Affinity Biosciences Cat# AF5378, RRID:AB_2837863.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CISH 1; CISH1; Cytokine inducible SH2 protein 1; JAB; JAK binding protein; JAK-binding protein; Janus kinase binding protein; SOCS 1; SOCS-1; Socs1; SOCS1_HUMAN; SSI 1; SSI-1; SSI1; STAT induced STAT inhibitor 1; STAT-induced STAT inhibitor 1; Suppressor of cytokine signaling 1; Supressor of cytokine signalling 1; TEC interacting protein 3; Tec-interacting protein 3; TIP 3; TIP-3; TIP3;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
O15524 SOCS1_HUMAN:

Expressed in all tissues with high expression in spleen, small intestine and peripheral blood leukocytes.

Description:
The SOCS (suppressor of cytokine signaling) gene family consists of a group of proteins that negatively regulate cytokine signal transduction. The SOCS family proteins contain a central SH2 domain and a carboxy-terminal region termed the “SOCS box.”
Sequence:
MVAHNQVAADNAVSTAAEPRRRPEPSSSSSSSPAAPARPRPCPAVPAPAPGDTHFRTFRSHADYRRITRASALLDACGFYWGPLSVHGAHERLRAEPVGTFLVRDSRQRNCFFALSVKMASGPTSIRVHFQAGRFHLDGSRESFDCLFELLEHYVAAPRRMLGAPLRQRRVRPLQELCRQRIVATVGRENLARIPLNPVLRDYLSSFPFQI

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Dog
100
Rabbit
100
Horse
90
Chicken
56
Sheep
0
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - O15524 As Substrate

Site PTM Type Enzyme
T185 Phosphorylation

Research Backgrounds

Function:

SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS1 is involved in negative regulation of cytokines that signal through the JAK/STAT3 pathway. Through binding to JAKs, inhibits their kinase activity. In vitro, also suppresses Tec protein-tyrosine activity. Appears to be a major regulator of signaling by interleukin 6 (IL6) and leukemia inhibitory factor (LIF). Regulates interferon-gamma mediated sensory neuron survival (By similarity). Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize JAK2. SOCS1 appears to be a negative regulator in IGF1R signaling pathway.

Subcellular Location:

Nucleus. Cytoplasmic vesicle.
Note: Detected in perinuclear cytoplasmic vesicles upon interaction with FGFR3.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in all tissues with high expression in spleen, small intestine and peripheral blood leukocytes.

Subunit Structure:

Interacts with multiple activated signaling proteins of the tyrosine kinase signaling pathway including JAK family kinases, TEC, KIT, GRB2 and VAV. Binding to JAKs is mediated through the KIR and SH2 domains to a phosphorylated tyrosine residue within the JAK JH1 domain. Binds the SH3 domain of GRB2 via diproline determinants in the N-terminus, and the N-terminal regulatory domain of VAV (By similarity). Interacts with the Elongin BC complex (ELOB and ELOC). Component of an ECS CBC(SOCS1) E3 ubiquitin-protein ligase complex which contains Elongin BC, CUL5, RBX1 and SOCS1 (By similarity). Interacts (via SH2 domain and SOCS box) with TRIM8 (By similarity). Interacts with AXL, CUL2 and FGFR3. Interacts with INSR (By similarity). Interacts with TRIM8.

Family&Domains:

The ESS and SH2 domains are required for JAK phosphotyrosine binding. Further interaction with the KIR domain is necessary for signal and kinase inhibition.

The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes. The Elongin BC complex binding domain is also known as BC-box with the consensus [APST]-L-x(3)-C-x(3)-[AILV] and is part of the SOCS box (By similarity).

Belongs to the SOCS1 family.

Research Fields

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Genetic Information Processing > Folding, sorting and degradation > Ubiquitin mediated proteolysis.   (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Type II diabetes mellitus.

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Prolactin signaling pathway.   (View pathway)

References

1). Berberine induces SOCS1 pathway to reprogram the M1 polarization of macrophages via miR-155–5p in colitis-associated colorectal cancer. European Journal of Pharmacology, 2023 (PubMed: 37059377) [IF=5.0]

2). HuoXueTongFu Formula Alleviates Intraperitoneal Adhesion by Regulating Macrophage Polarization and the SOCS/JAK2/STAT/PPAR-γ Signalling Pathway. MEDIATORS OF INFLAMMATION, 2019 (PubMed: 31772499) [IF=4.6]

3). ProS/Mer alleviates sepsis-induced neuromuscular dysfunction by inhibiting TLR4/MyD88/NF-κB signals. Research Square, 2022

Application: WB    Species: Rat    Sample:

Figure 6. Knockout of Mer reduced STAT1 activation and SOCS expression after CLP. Representative immunoblots and quantification showing the expression of TLR4 (A), NF-κB (B) was significantly increased in WT and Mer-/- group at day 4 after CLP; however, the expression of phosphorylated STAT1 (p-STAT1) (C), SOCS1 (D), and SOCS3 (E) were significantly decreased at day 4 after CLP. Data are expressed as fold change compared to the Sham + WT group; n = 5 rats per group. *P < 0.05 compared to Sham + WT group,

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.